Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | PATRIOT: ATR inhibitor monotherapy in advanced solid tumors

Kevin Harrington • 27 Sep 2019
ESMO 2019
General Ceralasertib
PATRIOT

Kevin Harrington, PhD, MBBS, Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK, discusses the PATRIOT trial (NCT02223923), a Phase I study to assess the tolerability, safety and biological effects of the ATR inhibitor AZD6738 as a monotherapy and in combination with palliative radiation therapy in patients with advanced solid tumors. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Kevin Harrington

2:37
Challenges of combining SOC chemotherapy/radiotherapy and immunotherapy in head and neck cancer
Kevin Harrington • 16 Mar 2022
2:42
Recent advances in targeted therapy for head and neck cancer
Kevin Harrington • 16 Mar 2022
1:59
Potential of immunotherapy in head and neck cancer
Kevin Harrington • 16 Mar 2022
3:01
Update on oncolytic viruses for cancer treatment
Kevin Harrington • 27 Sep 2019

Related Videos

0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
3:10
PALOMA: subcutaneous amivantamab in advanced solid tumors
Natasha Leighl • 17 Apr 2024
The content of VJOncology is intended for healthcare professionals